Level Bio AB (FRA:4MB) EBIT per Share: €-0.00 (TTM As of Mar. 2026)

What is Level Bio AB EBIT per Share?

Level Bio AB FRA:4MB +8.00% 23 EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus rates FRA:4MB with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 167 Medical Diagnostics & Research companies, Level Bio AB ranks worse than 83.23% on this metric.

Level Bio AB's EBIT per Share for the three months ended in Mar. 2026 was €0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was -17.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Level Bio AB's EBIT per Share or its related term are showing as below:

FRA:4MB' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -76.5 Med: 21.9 Max: 89
Current: -17.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Level Bio AB was 89.00% per year. The lowest was -76.50% per year. And the median was 21.90% per year.

FRA:4MB's 3-Year EBIT Growth Rate is ranked worse than
83.23% of 167 companies
in the Medical Diagnostics & Research industry
Industry Median: 13.2 vs FRA:4MB: -17.60

Level Bio AB's EBIT for the three months ended in Mar. 2026 was €-0.01 Mil.

Level Bio AB (FRA:4MB) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Level Bio AB EBIT per Share Related Terms

Level Bio AB EBIT per Share Historical Data

* Premium members only.

The historical data trend for Level Bio AB's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Level Bio AB EBIT per Share Chart

Level Bio AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

EBIT per Share

Get a 7-Day Free Trial

0.01

-0.00

-0.01

Level Bio AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT per Share	Get a 7-Day Free Trial															-0.00	-0.00	0.00	-0.00	0.00

23GF Score

Level Bio AB FRA:4MB

EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Level Bio AB EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Level Bio AB's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

	EBIT per Share		(A: Dec. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.32	/	68.399
=	-0.00

Level Bio AB's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

	EBIT per Share		(Q: Mar. 2026 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.011	/	68.399
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.00

Frequently Asked Questions Learn more about EBIT per Share →

What does a EBIT per Share of €-0.00 mean?

Level Bio AB (FRA:4MB) has a EBIT per Share of €-0.00 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Level Bio AB and its competitors. According to the industry distribution chart, Level Bio AB ranks #139 out of 167 companies in the Medical Diagnostics & Research industry, placing it in the top 83.2%.

Is Level Bio AB's EBIT per Share too high?

Level Bio AB's current EBIT per Share is €-0.00. Based on the distribution chart, Level Bio AB ranks #139 out of 167 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Level Bio AB has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.

How does Level Bio AB's EBIT per Share compare to TMO and DHR?

According to the Medical Diagnostics & Research industry distribution chart, Level Bio AB ranks #139 out of 167 companies for EBIT per Share. This places Level Bio AB in the lower half of its industry. The industry median EBIT per Share is 13.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT per Share for a Medical Diagnostics & Research company?

The median EBIT per Share among Medical Diagnostics & Research companies is 13.20, based on 167 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT per Share mean?

A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Level Bio AB and its competitors. For the Medical Diagnostics & Research industry, the median EBIT per Share is 13.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Level Bio AB's current EBIT per Share is €-0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Level Bio AB stock overvalued right now?

Level Bio AB (FRA:4MB) has a current EBIT per Share of €-0.00. The current EBIT per Share is €-0.00. Level Bio AB's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT per Share calculated?

EBIT per Share is calculated from a company's financial statements. For Level Bio AB (FRA:4MB), the current EBIT per Share is €-0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Level Bio AB Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies NGM:ATANA OSTO:PROGEN NGM:LUMITO XSAT:SPERM XSAT:GEAN OSTO:IDLDX TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN MTD DGX LH GH

Other Exchanges LEVBIO:Sweden

Address Vastra Finnbodavagen 4B, Nacka, Stockholm, SWE, 131 30

Website https://www.levelbio.se

Level Bio AB is a parent company and operates through subsidiary. It develops and manufactures diagnostic kits for the clinical market and also is a distributor and full service partner to molecular biology labs in the Nordics.

23GF Score

Get the complete analysis for FRA:4MB

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01

Price

View FRA:4MB Analysis

See EBIT per Share data for all stocks →